Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.

By A. Trotti, L. Bellm, J. Epstein, D. Frame, H. Fuchs, C. Gwede, E. Komaroff, L. Nalysnyk, M. Zilberberg. Radiotherapy and Oncology, 2003

1,145 citations recorded by the source corpus.

Subfields: Otorhinolaryngology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/2e564ca06919a8b7539de8b295033d470adecc33

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Radiology, Nuclear Medicine and Imaging

1. S. Bischoff

Citations in the corpus

• MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy (2014, positive): “Severe mucositis can necessitate a reduction in the chemotherapy dose or a treatment break in RT, which can negatively influence prognosis.(7,8) In addition, mucositis has a considerable economic impact, due to costs associated with symptom management, nutritional support, management of secondary in”
• ESPEN practical guideline: Clinical Nutrition in cancer. (2021, result): “PEG compared to radiologically inserted gastrostomies (RIG) appear to be associated with a lower risk of peritonitis and mortality [93].”